A Novel Molecular Mechanism Regulating ER α Activation/Repression and Degradation by BRCA1/1a/1b in Breast Cancer Cells| Chapter 10 | Current Practice in Medical Science Vol.10

 BRCA1 transformation is connected to forceful bosom malignant growths. We have found an agreement SUMO change site in the amino-terminal locale of the BRCA1/1a/1b proteins. The transformation in this conceivable SUMO acceptor site (K 10 9 R) diminished the proteins' ability to tie and stifle ligand-subordinate ERαtranscriptional action in bosom disease cells. Moreover, we found that Ubc9, a SUMO E2-forming catalyst, ties BRCA1 proteins. We distinguished the negligible BRCA1 space (1-182 aa) expected for both in vitro restricting to Ubc9 and controlling ER α action. BRCA1 Mutant #1 (K109 R) and disease inclining Mutant #4 (C61G) were debilitated in their capacity to both dilemma, as well as adjust Ubc9 interceded SUMO-subordinate/autonomous E2-prompted ER α transcriptional movement in bosom malignant growth cells. This is the primary review to show Ubc9 is associated with the BRCA1 E3 ubiquitin ligase-intervened corruption of ER. These discoveries highlight a clever job for BRCA1 in controlling the powerful patterns of SUMO and ubiquitin changes essential for ER α turnover. Liberation of this sub-atomic switch because of BRCA1 disappointment prompts bosom malignant growths that are either ER-negative or positive.

This study will assist in planning novel BRCA1 with working based customized designated therapy for these forceful bosom malignant growths.

Author(s) Details:

J. Xu,
Cancer Biology Program, Department of OB/GYN, Morehouse School of Medicine, 720 Westview Drive, SW, Atlanta, GA 30310-1495, USA

T. Watkins,
Cancer Biology Program, Department of OB/GYN, Morehouse School of Medicine, 720 Westview Drive, SW, Atlanta, GA 30310-1495, USA.

A. Reddy,
Cancer Biology Program, Department of OB/GYN, Morehouse School of Medicine, 720 Westview Drive, SW, Atlanta, GA 30310-1495, USA.

E. S. P. Reddy,
Cancer Biology Program, Department of OB/GYN, Morehouse School of Medicine, 720 Westview Drive, SW, Atlanta, GA 30310-1495, USA.

V. N. Rao,
Cancer Biology Program, Department of OB/GYN, Morehouse School of Medicine, 720 Westview Drive, SW, Atlanta, GA 30310-1495, USA.

Please see the link here: https://stm.bookpi.org/CPMS-V10/article/view/8073

Post-Translational Modification of SUMOylation and Cancer: A Brief Review | Chapter 09 | New Horizons in Medicine and Medical Research Vol. 3

 SUMOylation is a reversible post-translational modification that plays a role in DNA damage repair, immunological responses, carcinogenesis, cell cycle progression, and apoptosis. SUMO1, SUMO2/3, and SUMO4 are the four SUMO isoforms that have been identified. In complicated protein regulatory networks, many levels of regulation or SUMOylation may play a crucial role. SUMOylation dysfunction can lead to the development of illnesses and malignancies. As a result, SUMO could be employed as a cancer treatment target. The small ubiquitin-like modifier (SUMO) pathway is found in all eukaryotes and is involved in gene regulation, cellular signalling, and the preservation of genomic integrity. Maturation, activation, conjugation, ligation, and de-modification are all part of the SUMO catalytic cycle. The SUMO system has been related to a number of disorders, the most prominent of which being cancer. Carcinogenesis, DNA damage response, cancer cell proliferation, metastasis, and apoptosis are all affected by SUMOylation. SUMO has the potential to be a cancer treatment target. To better comprehend the role of SUMO in human disease, we present the basic concepts of the SUMO system and summarise the involvement of SUMO proteins in cancer cells in this review.

Author(S) Details

ZhI-Jian Han
Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R., China.

Yan-Hu Feng
Key Laboratory of the Digestive System Tumors of Gansu Province, Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R., China.

Bao-Hong Gu
Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R., China.

Yu-Min Li
Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R., China.

Hao Chen
Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R., China.

View Book:- https://stm.bookpi.org/NHMMR-V3/article/view/6338